Purpose National Comprehensive Cancer Network guidelines recommend 18 F-FDG-PET/CT, in addition to standard staging procedures, for systemic staging of newly diagnosed stage III breast cancer patients. However, factors in addition to stage may influence PET/CT utility. As breast cancers that are negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (triple-negative breast cancer, or TNBC) are more aggressive and metastasize earlier than other breast cancers, we hypothesized that receptor expression may be one such factor. This study assesses 18 F-FDG-PET/CT for systemic staging of newly diagnosed TNBC. Methods In this Institutional Review Board-approved retrospective study, our Healthcare Information System was screened for patients with TNBC who underwent 
Introduction
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ( 18 F-FDG-PET/CT) is useful for systemic staging of selected patients with newly diagnosed breast cancer, as the detection of unsuspected extraaxillary regional nodal metastases and distant metastases affects staging, treatment, and prognosis [1] . The question of which patients will benefit from systemic staging with 18 F-FDG-PET/CT is a matter of active debate [2] [3] [4] [5] . The 2015 National Comprehensive Cancer Network (NCCN) guidelines recommend systemic staging with 18 F-FDG-PET/CT, in addition to standard staging procedures, for patients with stage III breast cancer [6] . However, additional factors besides initial clinical stage may be important when determining whether a staging 18 F-FDG-PET/CT is clinically indicated. Tumor histology may be one such factor, given evidence that 18 F-FDG-PET/CT has a higher yield in patients with invasive ductal carcinomas (IDC) than in patients with invasive lobular carcinomas (ILC) [7, 8] . Patient age may be another factor, as younger patients with breast cancer have more aggressive malignancies [9, 10] , and 18 F-FDG-PET/CT demonstrates a high yield for unsuspected distant metastases in younger patients [11] .
Another potential factor for determining whether staging 18 F-FDG-PET/CT may be of value is the receptor phenotype of the primary breast malignancy. Molecular genetic classifications of breast cancer distinguish subclasses of breast cancer [12] [13] [14] [15] . While full molecular genetic classifications are still unlikely for most breast cancer patients, surrogate categorizations based on immunohistochemical receptor phenotypes is clinically standard [16, 17] . Expression of estrogen receptor (ER) and/or progesterone receptor (PR) in breast cancer cells predicts response to hormonal therapies. ER/PR positive breast cancers tend to be lower grade than comparable ER negative tumors and have a relatively better prognosis [18] . Overexpression of human epidermal growth factor 2 (HER2) in breast cancer cells is associated with aggressive biology and poorer prognosis [19] ; although, HER2 targeted antibody therapies have prolonged survival in both the metastatic and adjuvant settings [20] [21] [22] . Triple-negative breast cancers (TNBC) are a heterogenous group of breast cancers that do not express ER, PR, or HER2. Approximately 15 % of breast cancers are classified as triple-negative, and these tumors are very aggressive, with early metastases and poor prognosis [23, 24] . The time from diagnosis to metastasis in TNBC is very short (7-12 months) compared to other breast cancers [23] , and the most dramatic difference in survival between patients with TNBC and other breast cancers is seen within two years of diagnosis [24] . Given the propensity of TNBC for early metastases, we hypothesized that systemic staging with 18 F-FDG-PET/CT may be valuable in breast cancers with a triple-negative receptor phenotype earlier than clinical stage III. In this retrospective study, we evaluate the impact of systemic staging with 
Materials and methods

Study design and patients
This retrospective single-institution study was performed in compliance with the Health Insurance Portability and Accountability Act (HIPAA) and with Institutional Review Board (IRB) approval. The requirement to obtain informed consent was waived. The Memorial Sloan Kettering Cancer Center Healthcare Information System (HIS) was screened for patients with stage I to IIIC TNBC who underwent 18 F-FDG-PET/CT between January 2007 and December 2013 prior to beginning treatment with chemotherapy, hormonal therapy, or radiation. Electronic medical records (EMR) were reviewed and patients with the following characteristics were excluded: Known stage IV disease for the current malignancy prior to 18 F-FDG-PET/CT, symptoms suspicious for metastatic disease, prior or concurrent malignancies (except nonmelanoma skin cancer), systemic therapy or radiation prior to 18 F-FDG-PET/CT. Surgical management of the primary breast lesion and axillary nodes was allowed. Age at diagnosis, race, and time of followup and final survival status (alive, deceased) were recorded for each patient. Histology and grade were recorded for each tumor.
Determination of initial stage
Initial stages were determined according to the American Joint Committee on Cancer (AJCC) Staging Manual [25] . Initial clinical stage was determined from physical exam, mammography, breast ultrasound, and, if available, breast magnetic resonance imaging (MRI) and/or surgical findings.
PET/CT imaging and interpretation
All patients in this retrospective study had a staging 18 F-FDG-PET/CT. Prior to 18 F-FDG injection for PET/CT, patients fasted for at least six hours. Each patient was injected intravenously with 444-555 MBq of 18 F-FDG when plasma glucose was less than 200 mg/dL. After 18 F-FDG injection patients rested for a scheduled 60-minute uptake period followed by image acquisition on one of several GE Healthcare Discovery PET/CT systems. PET/CT scans were acquired supine from the mid-skull to the mid-thigh. In most cases, low-dose CT scans with oral contrast were obtained. Occasionally, intravenous contrast was administered. In all cases, attenuationcorrected images were reviewed on a picture-archiving and communication system workstation (PACS, GE Healthcare), displaying a maximum-intensity-projection image and multiplanar PET, CT, and PET/CT fusion images. According to standard 18 F-FDG-PET/CT reporting, uptake was considered abnormal when it was focal, was not considered physiologic or inflammatory, and had intensity greater than the local background. Suspicion for malignancy was based on the integration of metabolic information from the PET images, anatomic information from the CT images, and the fused PET/CT images. PET/CT studies were reinterpreted by a radiologist (G.U.) dually boarded in diagnostic radiology and nuclear medicine with nine years of PET/CT experience, blinded to the original PET/CT report and the results of other imaging modalities. Unsuspected local extra-axillary nodal metastases (internal mammary and supraclavicular) and distant metastases were recorded and, if they were noted on imaging, a new stage was assigned.
Verification of metastases
Histology was the preferred method to verify malignancy for 18 F-FDG-PET/CT findings. When histology was not available, follow-up imaging was used. Lesions had to show typical features of metastatic disease on initial imaging and show progression or response to treatment on follow-up imaging.
Statistical analysis
Medians and ranges were used to summarize continuous variables and frequencies, and percentages were used to summarize categorical variables, including distant metastases and upstaging. Race was grouped into African American, Asian, Caucasian, and other. The relationships between patient characteristics and upstaging were assessed using Fisher's exact test for categorical variables and the Wilcoxon Rank Sum test for continuous variables. Kaplan Meier curves as well as 3-year Kaplan Meier survival estimates were provided for initial stage IIB patients stratified by whether or not stage 4 disease was detected by 18 F-FDG-PET/CT, and the log rank test was used to assess the difference in survival.
P-values less than 0.05 were considered statistically significant and all analyses were performed using SAS 9.4 (The SAS Institute, Cary, NC).
Results
Patients with TNBC
A search of the Memorial Sloan Kettering Cancer Center Healthcare Information System identified 649 patients with newly diagnosed stage I-IIIC TNBC from January 2007 to December 2013. From these, 351 were excluded due to systemic or radiation therapy prior to (Figs. 1, 2, and 3) . 18 F-FDG-PET/CT demonstrated metastatic disease in the bone in eleven, liver in eight, distant nodes in eight, lung in seven, and pleura in one patient. Five patients had metastatic disease involving more than one organ site. In 26 of 30 patients, metastases were confirmed by pathology. In four patients (one liver, one bone, two distant nodes), metastases were confirmed by follow-up imaging. (Table 2) .
There were no proven false positives in this study, although only 26 of 30 patients demonstrating unsuspected distant metastases on 18 F-FDG-PET/CT were confirmed by pathology. Patients in this study were not down-staged by PET/CT results.
Regional nodal metastases Thirteen patients were upstaged by the identification of unsuspected local nodal metastases (Fig. 4) . Three of these nodal lesions were confirmed by pathology and the remainder by follow-up imaging.
Associations between clinical parameters and upstaging
No associations were found between patients that were upstaged to stage IV compared to those that were not upstaged to stage IV for age (median 58 years (range: 33-93 years) vs. 50 years 
Synchronous malignancies
18
F-FDG-PET/CT demonstrated seven unsuspected synchronous malignancies in six patients, including one non-small cell lung cancer, one renal cell carcinoma of the kidney, one grade 3 astrocytoma, one basal cell skin cancer, and three papillary thyroid cancers. One patient had two unsuspected primary malignancies, a non-small cell lung cancer, and a papillary thyroid cancer. All seven unsuspected synchronous malignancies were proven by pathology. 18 F-FDG-PET/ CT, and provides evidence of value in this patient population.
Survival of initial stage 2B patients stratified by
The survival of initially stage 2B patients who were upstaged to stage 4 by 18 F-FDG-PET/CT was significantly shorter than other initially stage 2B patients who were not upstaged to 4. This is consistent with the increased disease burden of stage 4 disease. The more accurate initial staging provided by 18 F-FDG-PET/CT will move patients with more advanced disease out of the 2B stage and may make the remaining stage 2B patients look like they have better survival rates than stage 2B patients in the past that did not benefit from 18 F-FDG-PET/CT imaging. This apparent improvement in survival due to better initial classification of disease stage has been called stage migration [26] .
Of note, the majority of patients in this study were early stage, including stage I (23/232, 10 %), stage IIA (82/232, 35 %) or stage IIB (87/232, 38 %) at initial diagnosis. Clinicians may already be using triple negative receptor status as a prompt to request systemic staging with 18 F-FDG-PET/CT at early initial stages. As none of the 23 initially stage I patients were shown to have unsuspected distant or nodal metastases on staging 18 F-FDG-PET/CT, this report provides reassurance that patients with stage I TNBC will be unlikely to benefit from systemic staging with [28] . Likewise, in Riedl et al., there were no statistically significant relationships between upstaging and receptor phenotype (p = 0.52) [11] . Statistical power in these studies was not reported.
Other studies have reported low rates (13/225, 6 %) of 18 F-FDG-avid false-positives for distant metastases on 18 F-FDG-PET/CT [29] . There were no proven false positives in this study, although only 26 of 30 patients demonstrating unsuspected distant metastases on 18 F-FDG-PET/CT were confirmed by pathology. It is possible that the four patients considered to have unsuspected distant metastases based on subsequent imaging could have been false positives.
While 18 F-FDG-PET/CT demonstration of unsuspected regional nodal disease will not have the same impact as the demonstration of unsuspected distant metastases, upstaging due to unsuspected nodal disease may still alter the course of treatment, such as extension of planned radiotherapy or surgery. F-FDG-PET/CT has also been known to detect unsuspected synchronous malignancies during the workup of an initial malignancy [30, 31] . In this study, six of 232 (2.6 %) patients had pathologically proven synchronous malignancies discovered on the staging 18 F-FDG-PET/CT, a percentage similar to prior reports.
A strength of this study is the large number of TNBC patients evaluated. The triple-negative receptor phenotype is a less common, more aggressive, phenotype of breast cancer, and the large cohort in this retrospective study allows an evaluation of 18 F-FDG-PET/CT for systemic staging of patients with TNBC.
The study has several limitations. The retrospective single institution study design lends itself to selection biases that are difficult to control. We have mentioned that a high percentage of patients in the study had stage I and II disease, resulting in an apparent selection bias for patients with lower stage disease. The reasons that patients with TNBC underwent systemic staging with 18 F-FDG-PET/CT at rates skewed more towards lower stages than for other groups of breast cancer are not clear, but we suggest that referring clinicians may be using the triple-negative receptor phenotype as a rationale to request 18 F-FDG-PET/CT. Most patients (26 of 30) classified as having distant metastases were histologically proven, which is a strong percentage for a retrospective study. Still, the lack of histological proof in four patients with distant metastases is a limitation. Further, most patients classified with unsuspected regional nodal metastases were not confirmed histologically. In general, upstaging for locoregional disease has less of an impact on clinical management, and thus less commonly prompts histologic confirmation. The lack of histologic verification of nodal disease limits the utility of the regional nodal 18 F-FDG-PET/CT findings. As most TNBC was IDC in histology and high in tumor grade (Table 1) , these comparisons may have been lower in statistical power.
Conclusion
Fifteen percent of patients with initial stage IIB TNBC demonstrated unsuspected distant metastases, and were upstaged to stage IV, on 
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